Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Expected to Rise, HC Wainwright Analyst Says

Posted by Stanley Muller on Aug 3rd, 2026

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) had its price target hoisted by equities researchers at HC Wainwright from $20.00 to $80.00 in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock.

Several other research firms also recently commented on ENLV. Zacks Research upgraded Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. Finally, Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enlivex Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $137.50.

View Our Latest Analysis on Enlivex Therapeutics

Enlivex Therapeutics Price Performance

Enlivex Therapeutics stock opened at $2.09 on Monday. The firm has a fifty day simple moving average of $8.04 and a two-hundred day simple moving average of $12.38. Enlivex Therapeutics has a twelve month low of $1.80 and a twelve month high of $31.50. The company has a market capitalization of $35.18 million, a PE ratio of -0.25 and a beta of 1.52.

Hedge Funds Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd grew its stake in shares of Enlivex Therapeutics by 44.8% in the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares during the last quarter. Invesco Ltd. bought a new position in Enlivex Therapeutics during the 4th quarter valued at approximately $43,000. Jane Street Group LLC raised its position in Enlivex Therapeutics by 244.1% during the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Enlivex Therapeutics in the 4th quarter worth approximately $33,000. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.